About Matchpoint Therapeutics
Matchpoint develops oral drugs for people with autoimmune and inflammatory diseases. Its broader discovery work also covers cancer. Its medicines attach permanently to disease-linked proteins, aiming to reach targets that other small-molecule drugs struggle to affect. It uses protein-mapping screens, machine learning and a custom compound library to find binding sites and design candidates.
Matchpoint is based in Watertown, Massachusetts, and Andre Turenne is president and chief executive officer. John O’Malley became chief medical officer in October 2026. It is privately held.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Nov 20, 2026 | $68,399,743of $150.0M target | 22 | $3.1M | EquityRule 506(b) | Form D ↗ |
| Oct 5, 2022 | Oct 17, 2022 | $41,999,994of $69.9M target | 15 | $2.7M | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $110,399,737 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Matchpoint Therapeutics's Form D filed Nov 20, 2026.

- Icosavax, director: Oct 18, 2019 · Apr 7, 2021
- Abcuro, director: Jan 22, 2021 (amended) · Aug 25, 2023 · Feb 19, 2025
- Matchpoint Therapeutics, director; managing director, sanofi ventures: Oct 17, 2022 · Nov 20, 2026
Bruce Booth appears on 36 Form D filings at 11 companies. Show all
- Miragen Therapeutics, director: May 27, 2009 (2 filings) · Sep 21, 2010 · Jan 3, 2012 (amended) · Apr 24, 2012 · Jun 26, 2014 (amended) · Feb 17, 2015 · Nov 12, 2015 · Feb 14, 2017
- Avila Therapeutics, director: Jul 31, 2009 · Jul 6, 2010 (amended)
- Larimar Therapeutics, director: Mar 1, 2010 · Mar 2, 2010 (amended) · Jul 12, 2011 · Aug 28, 2012 · Dec 5, 2012
- Unum Therapeutics, director: Oct 20, 2014 · Jun 25, 2015
- Lysosomal Therapeutics, director: Feb 11, 2015 · Oct 6, 2016 · Jan 18, 2017 (amended) · Nov 7, 2019
- Tectonic Therapeutic, director: Aug 3, 2016 · Feb 2, 2018
- Magenta Therapeutics, director: Nov 23, 2016 · May 5, 2017 · Apr 9, 2018
- Rodin Therapeutics, director: Sep 14, 2017
- Miragen Therapeutics, director: Nov 22, 2017 · Aug 6, 2018
- Vigil Neuroscience, director: Oct 5, 2020 · Jun 15, 2021 (amended) · Aug 25, 2021 · Aug 29, 2022
- Matchpoint Therapeutics, chairman; partner, atlas venture: Oct 17, 2022 · Nov 20, 2026


Who Invested in Matchpoint Therapeutics
Scroll table to see all columns →
| Announced | Round | Amount | Lead | Other investors | On the Form D | Source |
|---|---|---|---|---|---|---|
| Oct 7, 2026 | Series B | $150 million | Nextech Invest; Norwest | NewInvus; BB Biotech; T1D Fund; BOLD Longevity Growth.ReturningAccess Biotechnology; Atlas Venture; Sanofi Ventures; Digitalis Ventures. | First sale Oct 1, 2026, 6 days before the announcement; $68,399,743 of $150,000,000 from 22 investors. [7] | [3] |
| Oct 14, 2022 | Launch funding | $100 million | — | — | [5] |
Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
Why Investors Backed Matchpoint Therapeutics
Nextech pointed to MPT-062’s potential to change the management of many common immune-mediated inflammatory conditions. It saw the drug’s first-in-class mechanism as a precise oral way to address disease-causing T-cell overactivation. [3]
“MPT-062 could fundamentally change the management of many common immune-mediated inflammatory conditions with an oral medicine.”
“John brings highly relevant translational and clinical expertise in autoimmune and inflammatory diseases and an outstanding track record of building and leading effective teams to deliver innovative medicines for patients.”
Origin and Team
Nathanael Gray and Tinghu Zhang founded Matchpoint from Stanford University. Jianwei Che and Edward Chouchani were founders from Dana-Farber Cancer Institute. [1]
Product and Technology
Matchpoint’s view is that a lasting bond can raise potency, sharpen selectivity and sustain an effect after the drug clears. The approach can also reveal binding pockets that standard high-throughput screens miss. [1]
The Advanced Covalent Exploration platform, or ACE, uses broad screens across many proteins and focused screens on priority targets. Machine learning combines screen results with public data and protein-shape predictions. Its library includes fragments, lead-like compounds and drug-like compounds. [1]
Lead asset MPT-062 is an oral, first-in-class T-cell modulator. Clinical development is planned for 2027. [3]
A July 2025 agreement with Novartis funds an additional Matchpoint program. [3]
Use of Funds
- Series B proceeds will move MPT-062 to clinical proof of concept and advance the wider product pipeline. [3]
Milestones
Scroll table to see all columns →
| Date | What happened | Source | Coverage |
|---|---|---|---|
| Oct 14, 2026 | Matchpoint appointed John O’Malley as chief medical officer. | [4] | — |
| Oct 7, 2026 | Matchpoint announced that Kanishka Pothula and Brian Matesic would join its board. | [3] | FinSMEs ↗MedPath ↗ |
| Jul 2025 | Matchpoint and Novartis made an exclusive option-and-license deal for oral inhibitors aimed at several inflammatory diseases. | [6] | — |
We wrote this summary from public statements by Matchpoint Therapeutics and its investors. It is not investment advice.
Sources
- CompanyMatchpoint Therapeutics website · linked above ↑
- CompanyMatchpoint privacy policy
- CompanySeries B announcement
- CompanyJohn O’Malley appointment announcement
- CompanyOfficial launch announcement
- CompanyNovartis agreement announcement
- SECMatchpoint Therapeutics Form D, filed 2026-11-20 · linked above ↑
- SECMatchpoint Therapeutics Form D, filed 2022-10-17 · linked above ↑
- SECMatchpoint Therapeutics Inc. filing history
